The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox Article

Full Text via DOI: 10.1002/ejhf.2336 Web of Science: 000715123900012

Cited authors

  • Carbone S, daSilva-deAbreu A, Lavie CJ

Authors

Publication date

  • 2021

Published in

Category

International Standard Serial Number (ISSN)

  • 1388-9842

Number of pages

  • 4

Start page

  • 1673

End page

  • 1676

Volume

  • 23

Issue

  • 10